Page 3«..2345..1020..»

You are currently browsing the Nano Medicine category

Irbesartan Tablets Market 2019 Analysis by Key Players, Share, Trend, Segmentation and Forecast to 2026 – Instant Tech News

§ February 16th, 2020 § Filed under Nano Medicine Comments Off on Irbesartan Tablets Market 2019 Analysis by Key Players, Share, Trend, Segmentation and Forecast to 2026 – Instant Tech News

Verified Market Research recently added a research report titled, Irbesartan Tablets Market Size and Forecast to 2026. The research report represents the potential growth opportunities that prevail within the global market. The report is analyzed on the idea of secondary research methodologies acquired from historic and forecast data. The Irbesartan Tablets market is expected to grow substantially and thrive in terms of volume and value during the forecast period. The report will provide an insight into the growth opportunities and restraints that construct the market. Readers can gain meaningful comprehension about the future of the market.

Request a Sample of this report @ https://www.verifiedmarketresearch.com/download-sample/?rid=12088&utm_source=OMR&utm_medium=005

Top 10 Companies in the Irbesartan Tablets Market Research Report:

Apotex, Sanofi, Teva, Jiangsu Hengrui Medicine, Taj Pharmaceuticals, Zhuhai Rundu Pharmaceutica, Verdant Life Sciences

Competitive Landscape

The insightful research report on the Irbesartan Tablets market includes Porters five forces analysis and SWOT analysis to understand the factors impacting consumer and supplier behavior. It helps the reader understand the strategies and collaborations that players are that specialize in combat competition within the market. The comprehensive report provides a big microscopic check out the market. The reader can identify the footprints of the manufacturers by knowing about the worldwide revenue of manufacturers, the worldwide price of manufacturers, and production by manufacturers during the forecast period of 2015 to 2019.

Global Irbesartan Tablets Market: Drivers and Restraints

The report offers underlying drivers that compel the consumers to take a position within the products and services. The detailed information assists readers in understanding the requirements of consumer demands. The report provides drivers at the local and global levels to assist determine the economic process . This information will help readers decide potential strategies that can help them stay ahead in the competitive industry.

Restraints provided in this section of the report contrasts the drivers segment as it explains the factors that can hamper the growth of the Irbesartan Tablets market during the forecast period. Restraints play a pivotal role in the global and regional market as it bends the prospective opportunities in the market. Readers can weigh and asses the drivers and restraints before making any investments or strategies.

Global Irbesartan Tablets Market: Segment Analysis

The report includes major segments like product type and end-user that provide an array of components that determine the portfolio of the Irbesartan Tablets industry. Each type furnishes information regarding the sales value during the forecast period. The understanding of the segment directs the readers in recognizing the importance of things that shape the market growth.

Global Irbesartan Tablets Market: Regional Analysis

This section of the report provides detailed information about each region and how numerous factors of that particular region affect the growth of the Irbesartan Tablets market. The government policies, weather, politics, and other factors determine the longer term of the market differently in each region. The major regions covered in the report include North America, Europe, Asia Pacific, the Middle East, and Africa, and others.

Ask for Discount @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=12088&utm_source=OMR&utm_medium=005

Table of Content

1 Introduction of Irbesartan Tablets Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Irbesartan Tablets Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Irbesartan Tablets Market, By Deployment Model

5.1 Overview

6 Irbesartan Tablets Market, By Solution

6.1 Overview

7 Irbesartan Tablets Market, By Vertical

7.1 Overview

8 Irbesartan Tablets Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Irbesartan Tablets Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Get a Complete Market Report in your Inbox within 24 hours @ https://www.verifiedmarketresearch.com/product/irbesartan-tablets-market/?utm_source=OMR&utm_medium=005

About Us:

Verified market research partners with clients to provide insight into strategic and growth analytics; data that help achieve business goals and targets. Our core values include trust, integrity, and authenticity for our clients.

Analysts with high expertise in data gathering and governance utilize industry techniques to collate and examine data at all stages. Our analysts are trained to combine modern data collection techniques, superior research methodology, subject expertise and years of collective experience to produce informative and accurate research reports.

Contact Us:

Mr. Edwyne FernandesCall: +1 (650) 781 4080Email: [emailprotected]

TAGS: Irbesartan Tablets Market Size, Irbesartan Tablets Market Growth, Irbesartan Tablets Market Forecast, Irbesartan Tablets Market Analysis, Irbesartan Tablets Market Trends, Irbesartan Tablets Market

See more here:
Irbesartan Tablets Market 2019 Analysis by Key Players, Share, Trend, Segmentation and Forecast to 2026 - Instant Tech News

Read the Rest...

NANOBIOTIX Announces Fast Track Designation Granted By U.S. FDA For Investigation of First-in-class NBTXR3 In Head and Neck Cancer – Business Wire

§ February 15th, 2020 § Filed under Nano Medicine Comments Off on NANOBIOTIX Announces Fast Track Designation Granted By U.S. FDA For Investigation of First-in-class NBTXR3 In Head and Neck Cancer – Business Wire

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News:

NANOBIOTIX (Paris:NANO) (Euronext: NANO - ISIN: FR0011341205 the Company), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the investigation of NBTXR3 activated by radiation therapy, with or without cetuximab, for the treatment of patients with locally advanced head and neck squamous cell cancer who are not eligible for platinum-based chemotherapy.

Fast Track is a process designed to facilitate the development and accelerate the review of drugs for serious conditions and that have the potential to address unmet medical needs. The purpose is to expedite the availability of new treatment options for patients.

A product that receives Fast Track designation is eligible for1:

About NBTXR3

NBTXR3 is a first-in-class product designed to destroy tumors through physical cell death when activated by radiotherapy. NBTXR3 has a high degree of biocompatibility, requires one single administration before the first radiotherapy treatment session, and has the ability to fit into current worldwide radiotherapy radiation therapy standards of care. The physical mode of action of NBTXR3 makes it applicable across solid tumors such as lung, prostate, liver, glioblastoma, and breast cancers.

NBTXR3 is actively being evaluated locally advanced head and neck squamous cell carcinoma (HNSCC) of the oral cavity or oropharynx in elderly and frail patients unable to receive chemotherapy or cetuximab with limited therapeutic options. Promising results have been observed in the phase I trial regarding local control. In the United States, the company has started the regulatory process for the clinical authorization of a phase II/III trial in locally advanced head and neck cancers.

Nanobiotix is also running an Immuno-Oncology development program. The Company received FDA approval to launch a clinical trial of NBTXR3 activated by radiotherapy in combination with anti-PD-1 antibodies in locoregional recurrent (LRR) or recurrent and metastatic (R/M) HNSCC amenable to re-irradiation of the HN and lung or liver metastases (mets)from any primary cancer eligible for anti-PD-1.

The other ongoing NBTXR3 trials are treating patients with hepatocellular carcinoma (HCC) or liver metastases, locally advanced or unresectable rectal cancer in combination with chemotherapy, head and neck cancer in combination with concurrent chemotherapy, and prostate adenocarcinoma. Furthermore, the company has a large-scale, comprehensive clinical research collaboration with The University of Texas MD Anderson Cancer Center (9 new phase I/II clinical trials in the United States) to evaluate NBTXR3 across head and neck, pancreatic, thoracic, lung, gastrointestinal and genitourinary cancers.

About NANOBIOTIX: http://www.nanobiotix.com

Incorporated in 2003, Nanobiotix is a leading, clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell.

The Nanobiotix philosophy is rooted in designing pioneering, physical-based approaches to bring highly effective and generalized solutions to address unmet medical needs and challenges.

Nanobiotixs first-in-class, proprietary lead technology, NBTXR3, aims to expand radiotherapy benefits for millions of cancer patients. Nanobiotixs Immuno-Oncology program has the potential to bring a new dimension to cancer immunotherapies.

Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP). The Companys headquarters are in Paris, France, with a US affiliate in Cambridge, MA, and European affiliates in France, Spain and Germany

1https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/fast-track

Disclaimer

This press release contains certain forward-looking statements concerning Nanobiotix and its business, including its prospects and product candidate development. Such forward-looking statements are based on assumptions that Nanobiotix considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the reference document of Nanobiotix registered with the French Financial Markets Authority (Autorit des Marchs Financiers) under number R.19-018 on April 30, 2019 (a copy of which is available on http://www.nanobiotix.com) and to the development of economic conditions, financial markets and the markets in which Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements.

Read the original post:
NANOBIOTIX Announces Fast Track Designation Granted By U.S. FDA For Investigation of First-in-class NBTXR3 In Head and Neck Cancer - Business Wire

Read the Rest...

A puff of relief – The Tribune India

§ February 14th, 2020 § Filed under Nano Medicine Comments Off on A puff of relief – The Tribune India

Saurabh Goyal

Unprecedented air pollution in Indian cities has triggered major health concerns. Cases of respiratory disorders like bronchial asthma, cystic fibrosis and chronic obstructive pulmonary disease are on the rise. In response to these health challenges, pulmonary drug delivery through nebulisers is gaining widespread acceptance.

A market report published by Transparency Market Research has estimated that the Indian nebuliser market, which stood at Rs575.6 million in 2014, will reach Rs 4,703 million in 2023. Nebulisers are thus emerging as a preferred choice for the treatment of debilitating lung disorders. Considering that some medications work best with specific types of nebulisers, it is advisable to consult a doctor about the type of nebuliser suited for you, which would depend on the severity of your condition, symptoms, diagnosis and treatment regimen.

Which device best serves your purpose will also hinge on your lifestyle needs. If you spend a larger part of the day at office or school and if your job involves a lot of travelling, you should go for portable nebulisers as they are battery-operated and can be used on the go rather effortlessly.

While nebulisers enable people with lung conditions to inhale liquid-based medications into their airways to instantly relieve troublesome symptoms like wheezing and breathlessness and prevent acute attacks, the introduction of innovative technologies that enhance the efficacy is making these medical devices even more sought after.

Loss of medication in spray chamber remained a key concern in a compressor or jet nebuliser, but not any longer as now there are ultrasonic nebulisers providing efficient and faster drug delivery. The most commonly used are jet nebulisers; apart from being cost effective, they are suitable for all types of medications.

While jet nebuliser involves pressurised gas supply through a valve to assist in pushing medication toward the mouth, ultrasonic nebuliser uses electric current to produce high-frequency vibrations in a container and break up the fluid into aerosol particles. Mesh nebuliser, on the other hand, creates vibrations that enable the flow of medicine through a fine mesh so as to develop aerosol medication.

Chronic health conditions, coupled with an ageing population, have shifted the focus to personalised healthcare. This healthcare model involves adopting technologies which allow patients to manage their care on their own. Clearly, remote patient monitoring and virtual care by way of new digital technologies in portable medical devices intended for home use are now challenging the traditional healthcare model that involves frequent hospital visits and hospitalisation.

Types of nebulisers

Compressor jet nebuliser

Working mechanism: Used at most medical facilities, it works by forcing compressed air into the medication cup at high velocity to turn liquid medicine into aerosol

Pros

Cons

Ultrasonic nebuliser

Working mechanism: Piezoelectric crystal converts electric signal into high-frequency vibrations in liquid, forming aerosol using cavitation and capillary mechanisms

Pros

Cons

Mesh nebuliser

Working mechanism: A vibrating element pushes medication through microscopic holes of a membrane, generating aerosolof small droplets

Pros

Cons

The writer is executive director, Nureca

See the rest here:
A puff of relief - The Tribune India

Read the Rest...

Hepatocellular Carcinoma: 5 Things to Know – Medscape

§ February 14th, 2020 § Filed under Nano Medicine Comments Off on Hepatocellular Carcinoma: 5 Things to Know – Medscape

Managing patients who are at risk for or have been diagnosed with hepatocellular carcinoma (HCC), the most common form of liver cancer, can be daunting. Who should undergo surveillance and how? What is the next step once a liver lesion is identified? What treatment options can be offered?

Here are five things to know about HCC to help answer these difficult questions.

Cirrhosis precedes HCC in 80%-90% of patients, and one third of all patients with cirrhosis will develop HCC. The incidence of HCC is 1%-8% per year in all patients with cirrhosis (Table 1).

HCC surveillance is recommended for at-risk patient populations every 6 months, in line with the thresholds established by cost-effectiveness models. The rationale behind the frequency of imaging is that HCC has an average 6-month doubling time. For example, a 1-cm tumor not detected on ultrasound imaging will double in size to a 2-cm tumor in 6 months. Ultrasound will be more sensitive for detecting the tumor at this larger size, and the tumor will still be well within the size criteria for curative treatment options. Studies comparing surveillance intervals have also found 6 months to be optimal for improving survival.

Although not as common, HCC can occur without cirrhosis. Hepatitis B infection without cirrhosis is well recognized as leading to HCC. Hepatitis C infection with advanced fibrosis and nonalcoholic steatohepatitis (NASH) have also been associated with noncirrhotic HCC.[1,2,3]

Large prospective studies in the United States and Europe have established the relationship between NASH and HCC.Among the US population, the prevalence of nonalcoholic fatty liver disease (NAFLD) is 25% and NASH is 3%, with 40% of all patients with NASH progressing to advanced stages of fibrosis.

Although there are reports of liver cancer developing in the background of NASH without cirrhosis, the incidence is low, occurring at a rate of only 0.1% per year (Table 1).[4,5,6] However, with NAFLD affecting one third of the US population, the magnitude of noncirrhotic NASH contributing to HCC is worth noting.

Genetic factors, such as the presence of PNPLA3, also are associated with a high susceptibility to NASH and thus a risk for HCC.

Curing chronic hepatitis C infection is associated with a 71% risk reduction of incident HCC. This is by far the most effective way to decrease the risk for future liver cancer, especially in those with advanced fibrosis.

Patients with hepatitis C infection who have advanced liver fibrosis (stage F3) or cirrhosis should receive surveillance imaging before treatment is initiated with direct-acting antiviral agents (DAAs), and surveillance should be continued thereafter.

The presence of active HCC is associated with a slightly lower sustained virologic response to DAA therapy. For this reason, patients eligible for liver resection or ablation, and in some cases transplant, should defer DAA therapy until after such treatment is completed. Treatment with DAAs in patients with more advanced HCC should be weighed against tumor burden, degree of liver dysfunction, life expectancy, and patient preferences. DAAs are not associated with tumor recurrence after complete response to HCC treatment, but therapy for hepatitis C virus infection can be deferred 4-6 months to confirm complete control of the tumor.

Patients with a complete response to HCC therapy who are treated with DAAs require HCC surveillance indefinitely with CT scan or MRI every 3-6 months owing to a continued risk for HCC recurrence.

When a liver lesion is identified, cross-sectional dynamic phase imaging (CT scan or MRI) is performed using the Liver Imaging Reporting and Data System, which determines the likelihood of HCC by accounting for its typical features (eg, size, arterial enhancement, washout, enhancing capsule, growth). Hepatic protocol with quadruple-phase imaging (precontrast phase, arterial phase, portal venous phase, and delayed phase) is also recommended.

The choice of CT scan or MRI often depends on the technology available and institutional preference; however, a meta-analysis concluded that MRI is more sensitive than CT scan (80% vs 68%). Hepatobiliary-specific gadolinium (Gd-BOPTA and Gd-EOB-DTPA) is even more sensitive for small lesions, but timing in phase may be different than standard gadolinium.For patients with renal dysfunction or an allergy to CT scan contrast material, contrast-enhanced ultrasound is an option; the "contrast" agent is gas-filled microbubbles. Contrast-enhanced ultrasound can also be used to distinguish nontumor versus tumor thrombus.

Alpha-fetoprotein (AFP) is commonly used to help diagnose HCC. In addition to AFP, new tumor markers (AFP binding to Lens culinaris agglutinin, des-gamma-carboxyprothrombin) are available, with several emerging options in the pipeline.[7,8,9] Together, these biomarkers have an improved sensitivity in surveillance and diagnosis of HCC and may have a role in predicting response to treatment and prognosis.

Liver biopsy is now reserved for indeterminate lesions but may have a more robust role with the development of molecular therapies and precision medicine.

Curative therapies for HCC include resection, ablation, and liver transplantation.

Surgical resection is the treatment of choice for patients with early-stage cancer and preserved liver function, with a 5-year survival rate of approximately 70%. Recurrence is associated with the presence of microscopic vascular invasion. The risk and benefit of surgical resection should be weighed against local regional ablative therapies.

Ablation is an option for early-stage tumors not amenable to surgery. Radiofrequency ablation has replaced percutaneous ethanol ablation as the targeted therapy of choice. The best results with radiofrequency ablation were seen in newly diagnosed cancers with lesions < 2 cm, resulting in a 5-year survival rate of 47%-68%.Microwave coagulation therapy is a newer ablative approach that induces coagulate necrosis in tumors and may be more suitable for tumors in unfavorable locations or those > 3 cm in diameter.

Patients with HCC who have cirrhosis but do not have portal hypertension may be eligible for liver resection.However, if portal hypertension is present, transplant is the best curative option. In the United States, 20%-30% of all transplants are for HCC. After liver transplant, the 1-year survival rate is 94%, and the 3-year survival rate is 80%; the recurrence rate of HCC is 10%-15%.

Patients with HCC who are not eligible for curative options should be considered for palliative therapy, including transarterial chemoembolization and transarterial radioembolization, stereotactic body radiation therapy, or systemic chemotherapy. Palliative therapy may also be used for patients awaiting transplantation.

Until recently, sorafenib, an oral multikinase inhibitor, was the only approved systemic therapy for HCC. Now several systemic chemotherapy options are available for unresectable HCC in patients with otherwise well-preserved liver function (Table 2).[10,11,12,13,14,15,16,17]

Sheila L. Eswaran, MD, MS, is an associate professor in the hepatology section at Rush University Medical Center in Chicago. Her clinical and research interests are liver cancer and alcoholic hepatitis. She is co-chair of the American Liver Foundation Great Lakes Division Medical Advisory Committee.

Nancy S. Reau, MD, is chief of the hepatology section at Rush University Medical Center in Chicago, and a regular contributor to Medscape. She serves as editor of Clinical Liver Disease, a multimedia review journal, and recently as a member of HCVGuidelines.org, a web-based resource from the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America, as well as educational chair for the AASLD hepatitis C special interest group. She continues to have an active role in the hepatology interest group of the World Gastroenterology Organisation and the American Liver Foundation at the regional and national levels.

Follow Medscape on Facebook, Twitter, Instagram, and YouTube

View post:
Hepatocellular Carcinoma: 5 Things to Know - Medscape

Read the Rest...

Legal Marijuana Market is Projected to extend at a 53200 Million USD by the End of 2026 Mathematics Market Methods – Keep Reading

§ February 14th, 2020 § Filed under Nano Medicine Comments Off on Legal Marijuana Market is Projected to extend at a 53200 Million USD by the End of 2026 Mathematics Market Methods – Keep Reading

Legal Marijuana Players/Suppliers Profiles and Sales Data:Company, Company Basic Information, Manufacturing Base and Competitors, Product Category, Application and Specification with Sales, Revenue, Price and Gross Margin, Main Business/Business Overview.

The report on the global Legal Marijuana industry is just the resource that players need to strengthen their overall growth and establish a strong position in their business. It is a compilation of detailed, accurate research studies that provide in-depth analysis on critical subjects of the global Legal Marijuana industry such as consumption, revenue, sales, production, trends, opportunities, geographic expansion, competition, segmentation, growth drivers, and challenges. As part of geographic analysis of the global Legal Marijuana industry, the report digs deep into the growth of key regions and countries, including but not limited to North America, the US, Europe, the UK, Germany, France, Asia Pacific, China, and the MEA. All of the geographies are comprehensively studied on the basis of share, consumption, production, future growth potential, CAGR, and many other parameters.

Download Sample Copy of this Legal Marijuana Market Report: https://www.qyresearch.com/sample-form/form/1091409/global-legal-marijuana-market

Global Legal Marijuana Market is estimated to reach xxx million USD in 2020 and projected to grow at theCAGR of xx% during 2020-2026. According to the latest report added to the online repository of QY Research the Legal Marijuana market has witnessed an unprecedented growth till 2020. The extrapolated future growth isexpected to continue at higher rates by 2026.

The research report is broken down into chapters, which are introduced by the executive summary. Its the introductory part of the chapter, which includes details about global market figures, both historical and estimates. The executive summary also provides a brief about the segments and the reasons for the progress or decline during the forecast period. The insightful research report on the global Legal Marijuana market includes Porters five forces analysis and SWOT analysis to understand the factors impacting consumer and supplier behavior.

Global Legal Marijuana Market: Competitive Landscape

This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and production by manufacturers during the forecast period of 2015 to 2019.

The major players in the market include

Medicine ManCanopy GrowthAphriaAurora Cannabis Inc.mCig Inc

Market Segment Analysis

The research report includes specific segments by Type and by Application. Each type provides information about the production during the forecast period of 2015 to 2026. Application segment also provides consumption during the forecast period of 2015 to 2026. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type:

IndoorGreenhouse

Segment by Application:

RecreationalMedical

Global Legal Marijuana Market: Regional Analysis

The report offers in-depth assessment of the growth and other aspects of the Legal Marijuana market in important regions, including the U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, Taiwan, Southeast Asia, Mexico, and Brazil, etc. Key regions covered in the report are North America, Europe, Asia-Pacific and Latin America.

The report has been curated after observing and studying various factors that determine regional growth such as economic, environmental, social, technological, and political status of the particular region. Analysts have studied the data of revenue, production, and manufacturers of each region. This section analyses region-wise revenue and volume for the forecast period of 2015 to 2026. These analyses will help the reader to understand the potential worth of investment in a particular region.

Key Benefits for Stakeholders

Table Of Content

Get Customized Report in your Inbox within 24 hours:https://www.qyresearch.com/customize-request/form/1091409/global-legal-marijuana-market

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

See the original post:
Legal Marijuana Market is Projected to extend at a 53200 Million USD by the End of 2026 Mathematics Market Methods - Keep Reading

Read the Rest...

Lighted Mirror Medicine Cabinets Market is Projected to Worth US$ 1560 Million by 2026 End – Instant Tech News

§ February 14th, 2020 § Filed under Nano Medicine Comments Off on Lighted Mirror Medicine Cabinets Market is Projected to Worth US$ 1560 Million by 2026 End – Instant Tech News

The Latest Research Report on Lighted Mirror Medicine Cabinets Market size | Industry Segment by Applications, by Type, Regional Outlook, Market Demand, Latest Trends, Lighted Mirror Medicine Cabinets Industry Share & Revenue by Manufacturers, Company Profiles, Growth Forecasts 2026. Analyzes current market size and upcoming 5 years growth of this industry.

The report on the global Lighted Mirror Medicine Cabinets industry is just the resource that players need to strengthen their overall growth and establish a strong position in their business. It is a compilation of detailed, accurate research studies that provide in-depth analysis on critical subjects of the global Lighted Mirror Medicine Cabinets industry such as consumption, revenue, sales, production, trends, opportunities, geographic expansion, competition, segmentation, growth drivers, and challenges. As part of geographic analysis of the global Lighted Mirror Medicine Cabinets industry, the report digs deep into the growth of key regions and countries, including but not limited to North America, the US, Europe, the UK, Germany, France, Asia Pacific, China, and the MEA. All of the geographies are comprehensively studied on the basis of share, consumption, production, future growth potential, CAGR, and many other parameters.

Download Sample Copy of this Lighted Mirror Medicine Cabinets Market Report: https://www.qyresearch.com/sample-form/form/1091346/global-lighted-mirror-medicine-cabinets-market

Global Lighted Mirror Medicine Cabinets Market is estimated to reach xxx million USD in 2020 and projected to grow at theCAGR of xx% during 2020-2026. According to the latest report added to the online repository of QY Research the Lighted Mirror Medicine Cabinets market has witnessed an unprecedented growth till 2020. The extrapolated future growth isexpected to continue at higher rates by 2026.

The research report is broken down into chapters, which are introduced by the executive summary. Its the introductory part of the chapter, which includes details about global market figures, both historical and estimates. The executive summary also provides a brief about the segments and the reasons for the progress or decline during the forecast period. The insightful research report on the global Lighted Mirror Medicine Cabinets market includes Porters five forces analysis and SWOT analysis to understand the factors impacting consumer and supplier behavior.

Global Lighted Mirror Medicine Cabinets Market: Competitive Landscape

This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and production by manufacturers during the forecast period of 2015 to 2019.

The major players in the market include

KohlerIKEAKetchamDuravitBradleyCroydexRangaireAfinaStrasserForemostAmerican Pride

Market Segment Analysis

The research report includes specific segments by Type and by Application. Each type provides information about the production during the forecast period of 2015 to 2026. Application segment also provides consumption during the forecast period of 2015 to 2026. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type:

WoodPlasticMetalOther

Segment by Application:

HouseholdCommercial

Global Lighted Mirror Medicine Cabinets Market: Regional Analysis

The report offers in-depth assessment of the growth and other aspects of the Lighted Mirror Medicine Cabinets market in important regions, including the U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, Taiwan, Southeast Asia, Mexico, and Brazil, etc. Key regions covered in the report are North America, Europe, Asia-Pacific and Latin America.

The report has been curated after observing and studying various factors that determine regional growth such as economic, environmental, social, technological, and political status of the particular region. Analysts have studied the data of revenue, production, and manufacturers of each region. This section analyses region-wise revenue and volume for the forecast period of 2015 to 2026. These analyses will help the reader to understand the potential worth of investment in a particular region.

Key Benefits for Stakeholders

Table Of Content

Get Customized Report in your Inbox within 24 hours:https://www.qyresearch.com/customize-request/form/1091346/global-lighted-mirror-medicine-cabinets-market

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Continued here:
Lighted Mirror Medicine Cabinets Market is Projected to Worth US$ 1560 Million by 2026 End - Instant Tech News

Read the Rest...

Rodent Surgery Services Market Insights, Trends, Analysis, Types, Applications, key players, Market shares and Forecast 2017 2025 – Redhill Local…

§ February 14th, 2020 § Filed under Nano Medicine Comments Off on Rodent Surgery Services Market Insights, Trends, Analysis, Types, Applications, key players, Market shares and Forecast 2017 2025 – Redhill Local…

Business Intelligence Report on the Rodent Surgery Services Market

PMR, in a recently published market study, offers valuable insights related to the overall dynamics of the Rodent Surgery Services Market in the current scenario. Further, the report assesses the future prospects of the Rodent Surgery Services by analyzing the various market elements including the current trends, opportunities, restraints, and market drivers.

As per the report, the Rodent Surgery Services Market is set to grow at a CAGR of ~XX% over the forecast period 2017 2025 and exceed a value of ~US$ XX by the end of 2029. The report suggests that significant progress in technology, growing investments towards R&D projects, and increasing awareness related to curbing industrial waste are some of the primary factors that are expected to drive the growth of the Rodent Surgery Services Market during the assessment period.

ThisPress Release will help you to understand the Volume, growth with Impacting Trends. Click HERE To get SAMPLE PDF (Including Full TOC, Table & Figures) athttps://www.persistencemarketresearch.co/samples/15706

The presented report offers a microscopic view of the market scenario in different regions. The political and economic environment are thoroughly assessed to provide clarity on the growth prospects of the Rodent Surgery Services Market in each regional market.

Key Information that can be drawn from the Rodent Surgery Services Market Report:

Important queries related to the Rodent Surgery Services Market addressed in the report:

In order to get a strategic overview of the market,Access Research Methodology Prepared By Experts athttps://www.persistencemarketresearch.co/methodology/15706

Key Players

Some the market participants in the global rodent surgery services market which are commercial service providers are Charles River Laboratories International, Inc., Taconic Biosciences, Hilltop Lab Animals, Inc. and Envigo.

Institutional rodent surgery service providers are Hope Center for Neurological Disorders, University Laboratory Animal Resources, UNC School of Medicine and Stanford Medicine.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, types, technology and applications.

The report covers exhaustive analysis on:

Regional analysis includes

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Report Highlights:

Get Access To TOC Covering 200+ Topics athttps://www.persistencemarketresearch.co/toc/15706

Why Companies Trust PMR?

About us:

PMR is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Contact us:305 Broadway, 7th FloorNew York City, NY 10007United StatesPh.no. +1-646-568-7751

Read the rest here:
Rodent Surgery Services Market Insights, Trends, Analysis, Types, Applications, key players, Market shares and Forecast 2017 2025 - Redhill Local...

Read the Rest...

How nanotechnology is transforming medicine and the future of biology – Cosmopolis

§ February 14th, 2020 § Filed under Nano Medicine Comments Off on How nanotechnology is transforming medicine and the future of biology – Cosmopolis

Nanotechnology will transform our lifes, our economy, our future. The book of the Oxford professor of biological physics, Sonia Contera, Nano Comes To Life: How Nanotechnology Is Transforming Medicine and the Future of Biology (Amazon.com, Amazon.co.uk, Amazon.de, Amazon.fr), explains why and how.

Nanotechnologies allow scientists to visualize, interact with, manipulate and create matter at the nanometer scale. Nanotechnology can manipulate the building blocks of life and, therefore, life itself because proteins and DNA are nano-size.

According to Sonia Contera, health and longevity will be affected. Nanoscale machines can target individual cancer cells and deliver drugs more effectively. Nanoantibiotics can fight resistant bacteria and makes it possible to engineer tissues and organs for research, drug discovery and transplantation.

Nanotechnology directly links the macroscopic world of our perceptions with the nanoscopic world of individual biomolecules. To restore humans to perfect health, we would need to know how molecules work in a specific environment, why and how they malfunction in a desease and who to reach them, target them, deactivate or activate them. To cure, we need to go from the macroscopic size of the doctor to the nanometer scale of biomolecules. Sonia Conteras book tries to show how far we have come so far.

Nanotechnology has attracted physical scientists to biology. In the last decades of the 20th century, artificial nanomaterials and the tools of nanotechnology came into existence. Physcial scientists sought to know how and why biology first constructed itself using nano-size building blocks in the medium of (salty) water. The coupling of physics and chemistry give rise to biological function. Scientists focused on using nanotechnologys methods to learn the workings of proteins, DNA and other important nano-size biomolecules. They became biological physicists. Others, more practical, saw opportunities to design nanomaterials that could be used to address disease, improving on current pharmacological treatments; they became nanomedicine scientists.

Cross-disciplinary activity led to the development of tools specifically built for studying biological processes and their nano-actors in physiological conditions. Nano-bioscientists eroded the boundaries between materials sciences, physics, chemistry and biology.

The last decades saw the emergence of quantitative biology. Physicists try to create mathematical models of biological processes. They try to predict the behavior of specific biological processes in the computer (in silico), without experiments. This shall allow to progressively abandon the trial-and-error methods of the traditional biological, medical and pharmacological sciences which are slow, costly and often lead to inefficient new drugs.

Biological physics, the help of algorithms, the analysis of biological big data and AI will lead to increasingly (more) accurate and smart models of life. However, knowing the workings of the building blocks (of life) is not enough to predict the behaviour of the whole: at larger scales, biology exhibits behaviors that the smaller constituents do not exhibit, or that cannot be explained from the relationships between their molecular building blocks. Sonia Contera explains that this is because complexly organized matter presents collective phenomena arising from cooperative interactions between the building blocks (these properties emerge). Examples are cellular movements, mechanical vibrations in the brain, electrical signaling across the membranes of cells, changes in the shape or stiffness, none of which can be predicted from just knowing the molecules that constitute a particular structure. For instance, nanotechnology would allow simultanously targeting the molecular, the cellular and the issue-level biology of a tumor.

Biology, mathematics, physics and engineering sciences used in nanotechnology will radically change, the way we find, interpret and treat disease. Nanotechnology will transform biology and medicine. Sonia Contera explores the complexity of biology, the birth of DNA technology, DNA nanorobotics, nanomedicine, recreating tissues and organs, addresses issues such as fear of technology, technology and equality. These are just a few take-aways from this substantial book written for non-specialists.

The author writes that we as human beings have no other choice than to mature to become part of the whole in a physical, economic and social sense. We have to advance into the construction of a new relationship with nature that allows our survival.

Sonia Contera: Nano Comes To Life: How Nanotechnology Is Transforming Medicine and the Future of Biology. Hardcover, Princeton University Press, November 2019, 216 pages. Order the book, the source for this article, from Amazon.com, Amazon.co.uk, Amazon.de, Amazon.fr.

For a better reading, quotations and partial quotations in this book review are not put between quotation marks.

Book review added on February 14, 2020 at 16:14 German time.

See original here:
How nanotechnology is transforming medicine and the future of biology - Cosmopolis

Read the Rest...

Remyelination Potential of MS Therapy in Phase 2 Testing Evident in Animal Work, Study Says – Multiple Sclerosis News Today

§ February 13th, 2020 § Filed under Nano Medicine Comments Off on Remyelination Potential of MS Therapy in Phase 2 Testing Evident in Animal Work, Study Says – Multiple Sclerosis News Today

Clene Nanomedicines remyelination therapy candidate, CNM-Au8, showed a robust ability to stimulate the production of new myelin and increase the number of myelin-wrapped nerve fibers in the brain and spinal cord of animals in models of demyelinating disease, allowing mice to recover motor skills, a study reports.

Such preclinical data support the efficacy of this potential treatment, now being tested in clinical trials with multiple sclerosis (MS) patients.

These early findings were reported in the study Nanocatalytic activity of clean-surfaced, faceted nanocrystalline gold enhances remyelination in animal models of multiple sclerosis, published in the journalNature Scientific Reports.

In MS, the immune system attacks myelin, the protective sheath around nerve fibers or axons. Myelin is essential for the fast transmission of electrical signals between neurons, and its loss (demyelination) damages the integrity of nerve cells and their ability to communicate with each other.

Finding therapies that promote remyelination the recovery of myelin is a high priority for MS, the researchers noted.Such treatments could potentially repair demyelinating lesions in the central nervous system (the brain and spinal cord), restoring function to nerve cells affected by the disease.

Most approved MS therapies dampen the immune systems activity to prevent further myelin damage. However, they cannot undo existing damage or replace the myelin sheaths that have been lost.

Clene Nanomedicines lead compound, CNM-Au8, is a potential remyelination therapy for MS and other neurodegenerative disorders, including Parkinsons disease, and amyotrophic lateral sclerosis (ALS).

CNM-Au8 is a solution of gold (Au) nanoparticles with apatented crystal structure, named a clean-surfaced nanocrystal (CSN). According to the company, these nanocrystals have properties that make them highly biologically active, allowing them to facilitate certain energy-related reactions within cells.

In the brain, both neurons and supporting cells, includingoligodendrocytesthat produce myelin, need substantial amounts of energy to work. In fact, the brain consumes more than 25% of the bodys metabolic resources in order to sustain the efficient flux of information through its vast network of nerve fibers.

CNM-Au8 is expected to enhance key metabolic reactions in neurons and oligodendrocytes so to increase energy reserves within these cells, while decreasing the harmful molecules naturally generated by the cells metabolism. This process, which Clene calls nanocatalysis, is thought to improve the survival and function of neurons, and to support the ability of oligodendrocytes to create new myelin.

CNM-Au8 has demonstrated a good safety profile in Phase 1 studies in healthy volunteers, and preclinical studies in animal models of MS and other diseasesindicate the therapyhas both remyelination and neuroprotection effects.

Several ongoing Phase 2 trials are evaluating CNM-Au8 in neurodegenerative diseases, including two studies in people with non-active, relapsing MS.

REPAIR-MS (NCT03993171) is an open-label Phase 2 trial assessing the safety, pharmacokinetics (availability of the therapy in the body) and pharmacodynamics (its effects) of differing oral doses of CNM-Au8 in 24 adults with relapsing-remitting MS (RRMS). This study is currently enrolling eligible patients at theUniversity of Texas Southwestern. More details can be foundhere. It is expected to conclude in the fall.

Another Phase 2 trial, called VISIONARY-MS (NCT03536559), is investigating the efficacy and safety of CNM-Au8 in up to 150 adults with RRMS, who have chronic vision problems due to lesions (chronic optic neuropathy). This study is also recruiting at nine sites across Australia, and is supported by the National Multiple Sclerosis Society. Contact and site information is available here. Results from VISIONARY-MS are expected in 2021.

Now, the preclinical work by researchers at Clene Nanomedicine, Northwestern University, and George Washington Universityprovides additional evidence supporting the ability of these gold nanocrystalsto promote remyelination in cell and animal models of MS.

We are gratified at the publication of these data. These results establish the rationale for our ongoing Phase 2 clinical trial, VISIONARY-MS, which is designed to demonstrate the efficacy of CNM-Au8 for the treatment of chronic optic neuropathy in patients with non-active relapsing MS, Robert Glanzman, MD, chief medical officer of Clene Nanomedicine, said in a press release.

Researchers found that oral delivery of CNM-Au8 to mice and rat models of demyelination led to robust remyelination activity in the brain and spinal cord, leading to higher numbers of myelin-wrapped axons. Study data also showed that CNM-Au8 resulted in a greater migration of oligodendrocytes to lesion sites, and increased myelin production.

The remyelination promoted by CNM-Au8 was also matched by a significant recovery of physical abilities in the mice, evaluated using different locomotor and fine motor tests.

Working on cells in lab dishes, known as in vitro assays, the scientists showed that treating oligodendrocyte precursor cells with CNM-Au8 stimulated their differentiation and maturation, and the expression of myelin-related markers.

The gold nanocrystals were seen to act via a novel energy metabolism pathway that speeds the conversion of NADH to NAD+, a critical factor for sensing and producing energy in cells. CNM-Au8 also increased the levels of adenosine triphosphate (ATP), a small molecule used as fuel by cells, and turned on genes related to myelin production, collectively resulting in functional myelin generation, the researchers reported.

These results further validate our entirely new approach using therapeutic gold nanocatalysts as a mechanism to support the cellular viability and enhanced function of neurons and oligodendrocytes, saidKaren Ho, PhD, one of the studys authors and director of Translational Medicine at Clene Nanomedicine.

CNM-Au8 is one of a limited number of drugs being developed which have demonstrated remyelination capabilities. We believe these data exemplify a strong step forward in the development of a treatment to improve function in the lives of more than one million people living with MS in the U.S., Ho concluded.

Ana is a molecular biologist with a passion for discovery and communication. As a science writer, she looks for connecting the public, in particular patients and healthcare providers, with clear and quality information about the latest medical advances. Ana holds a Ph.D. in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in infectious diseases, epigenetics, and gene expression.

Total Posts: 1,053

Patrcia holds her PhD in Medical Microbiology and Infectious Diseases from the Leiden University Medical Center in Leiden, The Netherlands. She has studied Applied Biology at Universidade do Minho and was a postdoctoral research fellow at Instituto de Medicina Molecular in Lisbon, Portugal. Her work has been focused on molecular genetic traits of infectious agents such as viruses and parasites.

View original post here:
Remyelination Potential of MS Therapy in Phase 2 Testing Evident in Animal Work, Study Says - Multiple Sclerosis News Today

Read the Rest...

Massive growth on Nanomedicines Market By Top Key Players Abbott, GE Healthcare, Johnson & Johnson, Merck and Forecast 2020 To 2027 – Chronicle 99

§ February 13th, 2020 § Filed under Nano Medicine Comments Off on Massive growth on Nanomedicines Market By Top Key Players Abbott, GE Healthcare, Johnson & Johnson, Merck and Forecast 2020 To 2027 – Chronicle 99

The Nanomedicines Market 2020 Global Report serves as a document containing aggregate information, which promotes and assists in the estimation of all aspects of the Nanomedicines Market. It gives an image of the base and framework of the Nanomedicines market, which describes its favorable or restrictive points for global and regional growth. It describes the current situation of the Nanomedicines market by examining in depth various producers, unions, organizations, suppliers and industries under the Nanomedicines market. In addition, the Global Nanomedicines Market 2020 report provides meaningful information on segmentation, distribution network, estimated growth trends, monetary and trading terms, and many other crucial components relevant to the Nanomedicines market.

Request for sample of this report: http://www.contrivedatuminsights.com/Home/RequestaSample/10630

Market competition by Top Key Players: Abbott, GE Healthcare, Johnson & Johnson, Merck, Pfizer, CombiMatrix

Market Segmentation:

For product type segment, this report listed main product type of Nanomedicines market in gloabal and china: Nanoparticles, Nanoshells, Nanotubes, Nanodevices and Others

For end use/application segment, this report focuses on the status and outlook for key applications. End users sre also listed: Hospitals, Clinics, Research Institute

Profit and Sales Assessment Profits and sales are verified for various components of this international Nanomedicines market. Another crucial aspect, the price which plays a vital role in the development of sales can be evaluated in this section for several regions.

Segments and Benefits In pursuing the use of profits, this report examines the design and ingestion of its Nanomedicines market. The report also highlights the difference between usage and supply data, exports and imports.

Competition In this section, many global players in the Nanomedicines industry have been studied based on their company profile, product portfolio, capacity, price, cost and income.

Other analysis In addition to the information, demand and supply discussed above for the Nanomedicines economy, contact information for major producers, suppliers and large consumers can also be attributed.

Get More Discount: http://www.contrivedatuminsights.com/Home/GetSpecialPricing/10630

Additionally, it offers a clear understanding of global Nanomedicines market attributes such as production volume, values, market shares, and size. It also elaborates on global trading factors such as import, export, and local consumption. Moreover, it offers a competitive landscape of the global Nanomedicines market by providing the business profiles of various top-level industries. Collectively, it offers up-to-date informative data of global Nanomedicines market which will be beneficial to make informed decisions in the businesses.

North America, Latin America, Middle East, Asia-Pacific, Africa, Europe have been analyzed to study the global Nanomedicines market. Leading key players have been analyzed in several global regions. Furthermore, it makes use of graphical presentation techniques such as graphs, charts, tables, and pictures for better understanding to readers.

The key points of the report:

1.The report provides a basic overview of the industry including its definition, applications and manufacturing technology.

2.The report explores the international and Chinese major industry players in detail. In this part, the report presents the company profile, product specifications, capacity, production value, and 2013-2020 market shares for each company.

3.Through the statistical analysis, the report depicts the global and Chinese total market of Nanomedicines industry including capacity, production, production value, cost/profit, supply/demand and Chinese import/export.

4.The total market is further divided by company, by country, and by application/type for the competitive landscape analysis.

5.The report then estimates 2020-2027 market development trends of Nanomedicines industry. Analysis of upstream raw materials, downstream demand, and current market dynamics is also carried out.

6.The report makes some important proposals for a new project of Nanomedicines Industry before evaluating its feasibility.

Table of Contents (TOC)

Global Nanomedicines Market Research Report

Chapter 1 Global Nanomedicines Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export

Chapter 6 Production, Revenue (Value), Price Trend by Type

Chapter 7 Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Market Forecast

Get instant sample of this report: http://www.contrivedatuminsights.com/Home/RequestaSample/10630

Any special requirements about this report, please let us know and we can provide custom report.

Read more:
Massive growth on Nanomedicines Market By Top Key Players Abbott, GE Healthcare, Johnson & Johnson, Merck and Forecast 2020 To 2027 - Chronicle 99

Read the Rest...

Community gathers at teach-in to learn more about novel coronavirus – University of Pittsburgh The Pitt News

§ February 13th, 2020 § Filed under Nano Medicine Comments Off on Community gathers at teach-in to learn more about novel coronavirus – University of Pittsburgh The Pitt News

Pitt faculty and staff members gathered Wednesday evening to explain more about the novel coronavirus, the microscopic virus that has gained global attention.

Pitts Asian Studies Center hosted a Coronavirus Teach-in in a David Lawrence Hall lecture room nearly filled to capacity. The event featured a five-person panel staffed with experts across a variety of scholarly subjects, moderated by Michael Goodhart, the director of the Global Studies Center.

The presentations included background and contextual information about the outbreak, as well as preventative measures that can be taken to prevent the spread of the virus. The health experts on the panel also discussed the research underway to develop vaccines to treat the virus. The novel coronavirus has claimed the lives of more than 1,100 people globally, with 14 current confirmed cases in the United States.

Professor Amy Hartman, a researcher in the Center for Vaccine Research, highlighted the Wednesday announcement that the University is seeking to obtain samples of the novel coronavirus in an effort to develop an intervention, such as a vaccine.

The lab is a hub for researchers trying to understand pathogenesis, Hartman said. We are the only facility on Pitts campus that has the ability to work with emerging coronaviruses.

In order to provide some background on the virus, Dr. Megan Culler Freeman, a pediatric infectious diseases senior fellow in the School of Medicine, described the family tree of the novel coronavirus.

She said 2019-nCoV is just one strain of the coronavirus family of viruses, a group of RNA viruses that cause illnesses ranging from the common cold to more serious respiratory infections to the current disease under scrutiny. The most common COVID-19 symptoms include fever, shortness of breath and a severe cough.

Freeman mentioned two other coronavirus strains that are cousins to 2019-nCoV, Severe Acute Respiratory Syndrome and Middle East Respiratory Syndrome, which have caused outbreaks in the past. Scientists are gathering information about 2019-nCoV, which originated in Wuhan, China, by comparing it to these earlier viruses, but there are still unknown details surrounding how the novel coronavirus has spread to humans.

For SARS and MERS, it was identified that there were intermediate species, Freeman said. Scientists are still working on what might be the intermediary species between the bat and human for the newest strain of the coronavirus.

Another panel member, East Asian history professor Zhaojin Zeng, discussed how the culture and transportation system in China made the initial spread of the virus easier.

Trains make stops and Wuhan is located right in the center of this massive railroad network, Zeng said. This outbreak occurred in December 2019, then came Chinese New Year, people celebrating want to get together and have big family gatherings and dinners.

Although the virus outbreak has been most severe in and around the Wuhan area, history professor Mari Webel cautioned against strictly attributing the virus to a certain geographical region. Weber said while quarantine and isolation are beneficial in preventing the spread of diseases, they can also have consequences when they are implemented for the wrong reasons. Focusing on people or places of origin when thinking about prevention and control of global disease must be done carefully to avoid racializing a disease or stigmatizing a population, Webel said. For example, Asiatic cholera, that tag stuck and served to stigmatize certain traveling populations.

While there is still more research to be done on the novel coronavirus, health experts on the panel said this new strain is not unavoidable.

Dr. Kristen Mertz, a medical epidemiologist for the Allegheny County Health Department, said traditional public health strategies are applicable in minimizing the extent of the virus.

We try to identify and isolate cases so they dont infect other people, Mertz said. We also increase handwashing and use more personal protective equipment, such as gloves and masks and good disinfection techniques.

Freeman said among those who do contract 2019-nCoV, most fatalities arise from older people with other illnesses that already have weakened immune systems, or from overwhelmed health care professionals who are constantly surrounded by infected people.

When you think about how many people these doctors and nurses were already treating on a day-to-day basis, Freeman said, Im sure that everyone is giving it their best effort, but you can imagine the stress to the system.

While each presenter had their own specialty in analyzing 2019-nCoV, individual speakers also all emphasized the dangers of misinformation fueled by social media and sensational reporting.

Webel said it is vital to respect health organizations warnings and preventative strategies in order to avoid misleading information.

Consult CDC recommendations, there is good health journalism to consult, Webel said. There are resources out there that can give us the best information at the present time.

See original here:
Community gathers at teach-in to learn more about novel coronavirus - University of Pittsburgh The Pitt News

Read the Rest...

Medical Radiation Shielding Market Supply and Demand with Size (Value and Volume) by 2025 – TechNews.mobi

§ February 13th, 2020 § Filed under Nano Medicine Comments Off on Medical Radiation Shielding Market Supply and Demand with Size (Value and Volume) by 2025 – TechNews.mobi

Global Medical Radiation Shielding Market: Snapshot

The International Atomic Energy Agency describes the process of radiation protection or radiation shielding as the protection of humans from the negative impact they may receive when exposed to harmful values of ionizing radiation. For the sake of simplicity, most radiation shielding refers to the protection of human beings alone, as most technology that involves ionizing radiation refers to human contact. Ionizing radiation finds a growing scope of applications in the medical fields, due to which there is a very high chance of people suffering from radiation poisoning. It holds a strong potency of permanently damaging human tissues by affecting them at a microscopic level. The more common signs of exposure to ionizing radiation include radiation sickness, skin burns, and increased chances of cancer. The level of radiation exposure and the time duration of exposure can determine the signs of sickness that a patient may show.

Get Sample Copy of the Report @https://www.tmrresearch.com/sample/sample?flag=B&rep_id=854

There are different kinds of ionizing radiations and their reaction with the same radiation shield will be likewise different. This is why it is extremely important to use specific types of shielding materials against the different types of radiation. As a result, the global medical radiation shielding market needs to provide different types of shields for different types of radiation. It should also be noted that the shielding power will depend on the thickness, or the number of sheets used to create the shield. The calculations required for ascertaining the thickness of a radiation shield use a unit called halving thickness.

Global Medical Radiation Shielding Market: Overview

The global medical radiation shielding market is expected to grow at a positive rate between 2017 and 2025. The demand for medical radiation has shown a considerable surge in the last few years in response to the increasing incidence of chronic ailments, especially cancer. As per the World Health Organization, the new cases of cancer are expected to rise by 70% in the next two decades. The chronic ailment will therefore remain a leading cause of death across the world. Consequently, the demand for advanced treatment for fighting cancer is expected to remain high through the forecast period, thereby giving impetus to the global medical radiation shielding market.

The global medical radiation shielding market can be broadly classified on the basis of solution, product, end user, and region. For instance, sheet lead, shields, lead bricks, booths, barriers, lead lined doors & windows, x-ray rooms, lead glass, lead lined plywood, and lead curtains are a few of the key products available in the global medical radiation shielding market. By solution, the market can be bifurcated into diagnostic shielding and radiation therapy shielding.

The report covers growth drivers and restraints influencing the markets trajectory across all its segments. To present a holistic study, the report includes information obtained through proven research methodologies and from trusted industrial sources. It gauges the effect of Porters five forces and examines the investment feasibility for new players. Overall the report is intended to provide a clearer perspective of the global medical radiation shielding market to the readers.

Request TOC of the Report @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=854

Global Medical Radiation Shielding Market: Trends and Opportunities

Various factors support growth witnessed in the global medical radiation shielding market. The rising incidence of cancer will remain the chief driver, besides which the market will gain from the increasing use of nuclear medicine and radiation therapies for accurate diagnosis and cancer treatment. In addition, factors such as the increasing number of installation bases and diagnostic imaging centers, and the growing awareness about safety among people working in radiation-prone environment will aid the markets expansion. The market is also likely to benefit from the expansion of the healthcare industry worldwide and the upward moving number of people covered under insurance schemes.

Strong growth witnessed in emerging nations will create an array of opportunities for the medical radiation shielding market. However due to the high cost of MRI scanners, it may witness a few restraints in the forthcoming years.

Global Medical Radiation Shielding Market: Regional Outlook

Regionally, the global medical radiation shielding market will continue witnessing lucrative opportunities in North America, followed by Europe and Asia Pacific. Being a developed market, North America is an attractive hub for enterprises operating in the medical radiation shielding market. However, Asia Pacific will gradually emerge at fore during the course of the forecast period due to the growth witnessed by the market in India and China. Moreover, the rising awareness about radiation safety and the increasing funding in the healthcare sector will fuel the adoption of the medical radiation shielding technology in Asia Pacific.

Global Medical Radiation Shielding Market: Vendor Landscape

Some of the leading companies operating in the global medical radiation shielding market are Nelco, Inc., ETS-Lindgren, Radiation Protection Products, Ray-Bar Engineering Corp, Amray, and Global Partners in Shielding, Inc. among others. Policies adopted by the leading market players have a profound influence on overall operations. The report therefore includes their in-depth profiles covering recent marketing strategies, mergers and acquisitions, and product port-portfolios.

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

TMR Research,

3739 Balboa St # 1097,

San Francisco, CA 94121

United States

Tel: +1-415-520-1050

Tags: Medical Radiation Shielding Market

Read more here:
Medical Radiation Shielding Market Supply and Demand with Size (Value and Volume) by 2025 - TechNews.mobi

Read the Rest...

Sleep Medicine Market Research by Industry Growth Factors, Size, Top Companies Analysis, Share and Forecast 2020-2025 – TechNews.mobi

§ February 13th, 2020 § Filed under Nano Medicine Comments Off on Sleep Medicine Market Research by Industry Growth Factors, Size, Top Companies Analysis, Share and Forecast 2020-2025 – TechNews.mobi

Global Sleep Medicine Market Research Report offers detailed survey of market insight in communicative format, covering past from 2015-2019 and calculating 2020-2025.The predominant applications wise data has also been discussed at length in this research study with various Sleep Medicine market. It also provides complete professional and extensive analysis of global Sleep Medicine Market demand, standardization, deployment models, business challenges, industry opportunities and historical data with expert opinions.

Get Sample Copy of this Report https://www.orianresearch.com/request-sample/1435621

Global Sleep Medicine (OBC) Market: Drivers and Restrains

This report mainly elaborates the definition, types, applications and major players of Sleep Medicine market in details. Deep analysis about market status (2014-2019), enterprise competition pattern, advantages and disadvantages of enterprise products, industry development trends (2019-2024), regional industrial layout characteristics and macroeconomic policies, industrial policy has also be included. From raw materials to downstream buyers of this industry will be analyzed scientifically, the feature of product circulation and sales channel will be presented as well. In a word, this report will help you to establish a panorama of industrial development and characteristics of the Sleep Medicine market.

The major players in the marketinclude

Most important types of Sleep Medicine products covered in this report are:

Most widely used downstream fields of Sleep Medicine market covered in this report are:

A thorough evaluation of the restrains included in the report portrays the contrast to drivers and gives room for strategic planning. Factors that overshadow the market growth are pivotal as they can be understood to devise different bends for getting hold of the lucrative opportunities that are present in the ever-growing market. Additionally, insights into market experts opinions have been taken to understand the market better.

Market Segment Analysis

The research report includes specific segments by Type and by Application. Each type provides information about the production during the forecast period of 2015 to 2025. Application segment also provides consumption during the forecast period of 2015 to 2025. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Global Sleep Medicine (OBC) Market: Regional Analysis

The report offers in-depth assessment of the growth and other aspects of the Sleep Medicine (OBC) market in important regions, including the U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, Taiwan, Southeast Asia, Mexico, and Brazil, etc. Key regions covered in the report are North America, Europe, Asia-Pacific and Latin America.

The report has been curated after observing and studying various factors that determine regional growth such as economic, environmental, social, technological, and political status of the particular region. Analysts have studied the data of revenue, production, and manufacturers of each region. This section analyses region-wise revenue and volume for the forecast period of 2015 to 2025. These analyses will help the reader to understand the potential worth of investment in a particular region.

Global Sleep Medicine (OBC) Market: Competitive Landscape

This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and production by manufacturers during the forecast period of 2015 to 2019.

Order a copy of Global Sleep Medicine Market Report @https://www.orianresearch.com/checkout/1435621

Table of Contents

1 Sleep Medicine (OBC) Market Overview

2 Market Competition by Manufacturers

3 Production Capacity by Region

4 Global Sleep Medicine (OBC) Consumption by Regions

5 Production, Revenue, Price Trend by Type

6 Global Sleep Medicine (OBC) Market Analysis by Application

7 Company Profiles and Key Figures in Sleep Medicine (OBC) Business

8 Sleep Medicine (OBC) Manufacturing Cost Analysis

9 Marketing Channel, Distributors and Customers

10 Market Dynamics

11 Production and Supply Forecast

12 Consumption and Demand Fprecast

15 Methodology and Data Source

About Us

Orian Research is one of the most comprehensive collections of market intelligence reports on the World Wide Web. Our reports repository boasts of over 500000+ Industry and country research reports from over 100 top publishers. We continuously update our repository so as to provide our clients easy access to the worlds most complete and current database of expert insights on global industries, companies, and products. We also specialize in custom research in situations where our syndicate research offerings do not meet the specific requirements of our esteemed clients.

Contact Us

Ruwin Mendez

Vice President Global Sales & Partner Relations

Orian Research Consultants

US: +1 (415) 830-3727 | UK: +44 020 8144-71-27

Email:[emailprotected]

See the rest here:
Sleep Medicine Market Research by Industry Growth Factors, Size, Top Companies Analysis, Share and Forecast 2020-2025 - TechNews.mobi

Read the Rest...

NIH Is Looking For A Drugmaker To Develop Its Potential COVID-19 Vaccine But No One Is Raising Their Hand – Kaiser Health News

§ February 12th, 2020 § Filed under Nano Medicine Comments Off on NIH Is Looking For A Drugmaker To Develop Its Potential COVID-19 Vaccine But No One Is Raising Their Hand – Kaiser Health News

In the past drugmakers have stepped up during times of public crisis to take over the development of a drug, but that can also leave them burned in the end. I dont work for the companies, Im not like a drug company fan, said Ron Klain, who served as Ebola czar in the Obama administration. But theres no question that a lot of them lost a lot of money trying to produce an Ebola vaccine.

Stat:Major Drug Makers Haven't Stepped Up To Make NIH Coronavirus VaccineNo major pharmaceutical company has come forward to say it would manufacture a vaccine for the novel coronavirus currently being developed by the National Institutes of Health, a top U.S. official acknowledged Tuesday, a reality that he called very difficult and very frustrating. The comments by Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, highlight how challenging it could be to translate the NIHs work, being undertaken in partnership with the biotech company Moderna Therapeutics, into a vaccine that could be marketed. (Florko, 2/11)

The Washington Post:Global Experts Study Promising Drugs, Vaccines For New VirusThe World Health Organization convened outside experts Tuesday to try to speed the development of tests, treatments and vaccines against the new coronavirus, as doctors on the front lines experiment on patients with various drugs in hopes of saving lives in the meantime. The 400 scientists participating in the two-day meeting many remotely will try to determine which approaches seem promising enough to advance to the next step: studies in people to prove if they really work. (Keaten and Cheng, 2/11)

Philadelphia Inquirer:Inside A Philadelphia Lab, Scientists Race To Design A Coronavirus VaccineFaraz Zaidi and Daniel Park peered at a series of small, black blots that appeared on a clear sheet of plastic confirming they had created a type of protein that, until January, was unknown to science. It was a signal alerting them to the presence of the microscopic spikes on a coronavirus the infectious microbe that, at last count, had killed more than 1,000 people in China. (Avril, 2/11)

WBUR:There's No Specific Drug That Kills Coronavirus. But Doctors Have Ways To Treat ItEven though the coronavirus disease that has sickened tens of thousands of people in China is new to science, doctors have a pretty good idea about how to treat it. COVID-19, as it is now named, attacks the lungs. Doctors see similar symptoms from other diseases all the time, especially from serious cases of the flu.There's no specific drug that can kill this virus. So doctors provide what's known as supportive care, says Dr. Laura Evans, a critical care specialist at the University of Washington and a member of the Society of Critical Care Medicine's Leadership Council. (Harris, 2/11)

And in other news

Stat:Understanding Pandemics: Key Questions As The Coronavirus SpreadsThe word pandemic is not a comforting one. And yet it is increasingly being bandied about in connection with the spread of the novel coronavirus that emerged from China. U.S. health officials have been signaling for nearly two weeks now that a coronavirus pandemic may be on the horizon. While stressing that the virus presents only a low risk to Americans right now, the director of the National Institute of Allergy and Infectious Diseases, Dr. Anthony Fauci, acknowledged Tuesday that that might not remain the case for long. (Banswell, 2/12)

Bloomberg:Early Coronavirus Genetic Data May Have Forewarned OutbreakChina didnt release key genetic data on the coronavirus until about two weeks after it emerged that a new SARS-like illness may be sickening people, highlighting the need for outbreak detection systems to incorporate modern scientific tools. Insufficient attention was paid to the information doctors had gathered about the genetic sequence of the novel coronavirus, scientists said in a commentary paper in the Lancet medical journal Tuesday. The authors, who include two members of the World Health Organizations emergency committee, said this wasnt the result of a cover-up or deliberate delay, but rather the absence of mechanisms to inform outbreak warning systems. (Gale, 2/11)

Go here to see the original:
NIH Is Looking For A Drugmaker To Develop Its Potential COVID-19 Vaccine But No One Is Raising Their Hand - Kaiser Health News

Read the Rest...

Health: Is this company onto an alternative to stem cell therapy? – Stockhead

§ February 12th, 2020 § Filed under Nano Medicine Comments Off on Health: Is this company onto an alternative to stem cell therapy? – Stockhead

Many regenerative medicine companies on the ASX specialise in stem-cell therapies but Exopharm (ASX:EX1) is pursuing exosomes instead.

Exosomes, also known as Extra-corporeal Vesicles, are microscopic cellular couriers. These shift proteins and genetic information between cells and this can promote regeneration and healing of damaged cells.

In other words, they can tell cells they are a healthier, younger version of themselves successfully.

The challenge is that there are plenty of products on the black market but clinical research has been limited. But the research that has been done has shown exosomes can be lower risk, have higher scalability and even a superior therapeutic capacity.

This morning Exopharm announced BioMAP testing results of both its exosome products Plexaris and Cevaris.

These were compared with 4,500 experimental and sold medicines across a penal of 12 human primary cell-based systems.

Both products were deemed safe and had notable biological activity in tissue remodelling, inflammation and immune-modulatory related activities.

The results also showed that both products were not cytotoxic and did not cause anti-proliferative effects.

CEO Dr Ian Dixon declared the results were very positive.

The testing showed that both Plexaris and Cevaris had different and distinct activities to comparison drugs, he said.

This confirms our belief that exosomes are a distinct and potentially new class of medicine, different from existing medicines.

Exopharm recently began a phase one human clinical trial in Plexaris in a wound healing context. The company also has a technology (LEAP) that purifies exosomes for clinical purposes a necessary step to separate them from other biological fluids like serum.

Exopharm listed in December 2018 and rallied for a few months before a retreat in the second half of last year. But it is still above its IPO price and climbed 11.5 per cent this morning.

READ MORE:IPO Watch: Exopharm wants to raise $7m to help you live longer

National Veterinary Care (ASX:NVL) is about to be acquired but that hasnt stopped it adding four more vet clinics to its portfolio. Upon settlement of the deals, expected next month, it will own 107 clinics.

Get the latest Stock & Small Caps news and insights direct to your inbox.

Read the rest here:
Health: Is this company onto an alternative to stem cell therapy? - Stockhead

Read the Rest...

NANOBIOTIX announces fast track designation granted by FDA for investigation of first-in-class NBTXR3 In head and neck cancer – DOTmed HealthCare…

§ February 12th, 2020 § Filed under Nano Medicine Comments Off on NANOBIOTIX announces fast track designation granted by FDA for investigation of first-in-class NBTXR3 In head and neck cancer – DOTmed HealthCare…

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Paris:NANO) (Euronext: NANO - ISIN: FR0011341205 the Company), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the investigation of NBTXR3 activated by radiation therapy, with or without cetuximab, for the treatment of patients with locally advanced head and neck squamous cell cancer who are not eligible for platinum-based chemotherapy.

Fast Track is a process designed to facilitate the development and accelerate the review of drugs for serious conditions and that have the potential to address unmet medical needs. The purpose is to expedite the availability of new treatment options for patients.

A product that receives Fast Track designation is eligible for1:

Ad StatisticsTimes Displayed: 61314Times Visited: 843

NBTXR3 is a first-in-class product designed to destroy tumors through physical cell death when activated by radiotherapy. NBTXR3 has a high degree of biocompatibility, requires one single administration before the first radiotherapy treatment session, and has the ability to fit into current worldwide radiotherapy radiation therapy standards of care. The physical mode of action of NBTXR3 makes it applicable across solid tumors such as lung, prostate, liver, glioblastoma, and breast cancers.

NBTXR3 is actively being evaluated locally advanced head and neck squamous cell carcinoma (HNSCC) of the oral cavity or oropharynx in elderly and frail patients unable to receive chemotherapy or cetuximab with limited therapeutic options. Promising results have been observed in the phase I trial regarding local control. In the United States, the company has started the regulatory process for the clinical authorization of a phase II/III trial in locally advanced head and neck cancers.

Here is the original post:
NANOBIOTIX announces fast track designation granted by FDA for investigation of first-in-class NBTXR3 In head and neck cancer - DOTmed HealthCare...

Read the Rest...

Dr. Mak Jawadekar Joins the Board of Directors of NanoViricides, Inc. – Yahoo Finance

§ February 12th, 2020 § Filed under Nano Medicine Comments Off on Dr. Mak Jawadekar Joins the Board of Directors of NanoViricides, Inc. – Yahoo Finance

SHELTON, CT / ACCESSWIRE / February 12, 2020 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), a leader in developing novel nanomedicines to treat viral diseases, reports that Dr. Makarand "Mak" Jawadekar, a veteran Pharma industry expert professional, has been duly appointed as an Independent Director to its Board of Directors. He is also appointed as a member of the Board's Audit Committee, Nomination Committee, and Compensation Committee.

Dr. Mak Jawadekar has been serving as a strategic advisor to pharmaceutical and biotechnology companies through his independent consultancy since 2010. He has over 35 years of experience in the Pharma Industry spanning both Business and Research activities. He has extensive experience in joint ventures, alliance management, contracting, outsourcing, benchmarking, performance metrics, pharmaceutical research and development, drug delivery technologies, formulations, clinical supply manufacturing and packaging, clinical trial materials, pharmaceutics, and pharmaceutical sciences. He also has deep knowledge and global experience working across the United States, Europe, India, and other parts of Asia, including Japan and China. He has helped create several Pharma R&D Partnerships, Joint Ventures, and Collaborations during his career.

"We are very pleased to announce that Dr. Jawadekar has joined our Board. His breadth and depth of experience in developing collaborations and alliances would be highly valuable to the Company, as we advance our drug candidates further into the regulatory pathway," said Anil R. Diwan, PhD., Executive Chairman of the Board and President of the Company.

Prior to his consultancy practice, Dr. Jawadekar was at Pfizer, Inc., as Director, Portfolio Management & Analytics, and as Vice President, Asia Colleague Resource Group, in the Pfizer Global R&D division. Mak held roles of increasing responsibility from 1982 to 2010 while at Pfizer, in technical, management, and business development positions. In these roles, he has worked in the areas of Drug Delivery Technology Assessment, Strategic External Alliance Management, Strategic CMC, Pharma R&D, Clinical Manufacturing, Manufacturing Technology Transfer and Scale-up, beginning as a research scientist in formulations development.

Dr. Jawadekar has presented at many professional meetings and has participated in various Panel Discussions/Round Tables around the globe. US President George W. Bush invited Dr. Jawadekar to accompany him on a trip to India in 2006. Recently, he accompanied Honorable Congressman Todd Rokita (R) Indiana, on a business mission to India in 2019. He has accompanied Presidents of Pfizer R & D to India in 2007 and also in 2009. During February 2018, he worked with Mr. Tonino Lamborghini, Chairman, Tonino Lamborghini S.p.A. of Italy to establish strategic collaborations in India, working through India's Prime Minister Narendra Modi.

Dr. Jawadekar serves on the boards of two other public companies, namely: Preveceutical Medical Inc. (PREV), and Cardax, Inc. (CDXI), as an independent board member. He also serves on the Strategic and Scientific Advisory Boards of a number of companies, including Actinium Pharma (ATNM), Saama Technologies, Inc., Diant Pharma, Inc., and Tonino Lamborghini SpA, Italy. He also serves as a member of the Board of Directors at Abilities Inc., a NY based, non-profit organization.

Mak holds a Ph.D. in Pharmaceutics from the University of Minnesota, and was honored with an honorary D.Sc. degree by DYP Mumbai University, recommended by the President of India, in February, 2011.

The Company believes Dr. Jawadekar's long history as a pharmaceutical and biotech professional, particularly in alliance development and management, in business strategy, and in pharmaceutical sciences, and CMC in drug delivery, render him well qualified to serve as an independent member of the Board of Directors.

In another news, the Company advises that Mr. James Sapirstein is leaving the Board of Directors of the Company. He tendered his resignation due to increased workload in his role as the CEO of AzurRx BioPharma, Inc. (AZRX). Mr. Sapirstein joined AzurRx as CEO and President in October 2019, and had advised the Company of his intention to retire from our Board of Directors. The Company and Mr. Sapirstein have no differences of opinion and Mr. Sapirstein has continued to advise the Company on various strategic aspects as the Company is progressing toward filing its first IND application, and in its financing efforts.

Story continues

"We sincerely appreciate Mr. Sapirstein's various contributions to the Company as an independent Director, and we wish him continued success in his career," said Mr. Stan Glick, Lead Independent Director, on behalf of the Board and the Executive Management of the Company.

About NanoViricidesNanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. Our lead drug candidate is NV-HHV-101 with its first indication as dermal topical cream for the treatment of shingles rash. The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. The Company's technology is based on broad, exclusive, sub-licensable, field licenses to drugs developed in these areas from TheraCour Pharma, Inc. This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products. FDA refers to US Food and Drug Administration. IND application refers to "Investigational New Drug" application. CMC refers to "Chemistry, Manufacture, and Controls".

Contact:NanoViricides, Inc.info@nanoviricides.com

Public Relations Contact:MJ ClyburnTraDigital IRclyburn@tradigitalir.com

SOURCE: NanoViricides, Inc.

View source version on accesswire.com: https://www.accesswire.com/576087/Dr-Mak-Jawadekar-Joins-the-Board-of-Directors-of-NanoViricides-Inc

Visit link:
Dr. Mak Jawadekar Joins the Board of Directors of NanoViricides, Inc. - Yahoo Finance

Read the Rest...

NANOBIOTIX Announces Fast Track Designation Granted By U.S. FDA For Investigation of First-in-class NBTXR3 In Head and Neck Cancer – Yahoo Finance

§ February 11th, 2020 § Filed under Nano Medicine Comments Off on NANOBIOTIX Announces Fast Track Designation Granted By U.S. FDA For Investigation of First-in-class NBTXR3 In Head and Neck Cancer – Yahoo Finance

"The FDAs decision to grant Fast Track designation is not only important for the development of NBTXR3 activated by radiation therapy, which is now eligible for accelerated approval and priority review, but even more critically it underscores the unmet needs and limited options of patients with locally advanced head and neck cancer. The available public data and our development plans moving forward give us confidence that NBTXR3 could significantly improve treatment outcomes for patients. Fast Track development in head and neck cancer is a major step forward." Laurent Levy, CEO of Nanobiotix

Regulatory News:

NANOBIOTIX (Paris:NANO) (Euronext: NANO - ISIN: FR0011341205 the "Company"), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the investigation of NBTXR3 activated by radiation therapy, with or without cetuximab, for the treatment of patients with locally advanced head and neck squamous cell cancer who are not eligible for platinum-based chemotherapy.

Fast Track is a process designed to facilitate the development and accelerate the review of drugs for serious conditions and that have the potential to address unmet medical needs. The purpose is to expedite the availability of new treatment options for patients.

A product that receives Fast Track designation is eligible for1:

About NBTXR3

NBTXR3 is a first-in-class product designed to destroy tumors through physical cell death when activated by radiotherapy. NBTXR3 has a high degree of biocompatibility, requires one single administration before the first radiotherapy treatment session, and has the ability to fit into current worldwide radiotherapy radiation therapy standards of care. The physical mode of action of NBTXR3 makes it applicable across solid tumors such as lung, prostate, liver, glioblastoma, and breast cancers.

NBTXR3 is actively being evaluated locally advanced head and neck squamous cell carcinoma (HNSCC) of the oral cavity or oropharynx in elderly and frail patients unable to receive chemotherapy or cetuximab with limited therapeutic options. Promising results have been observed in the phase I trial regarding local control. In the United States, the company has started the regulatory process for the clinical authorization of a phase II/III trial in locally advanced head and neck cancers.

Nanobiotix is also running an Immuno-Oncology development program. The Company received FDA approval to launch a clinical trial of NBTXR3 activated by radiotherapy in combination with anti-PD-1 antibodies in locoregional recurrent (LRR) or recurrent and metastatic (R/M) HNSCC amenable to re-irradiation of the HN and lung or liver metastases (mets)from any primary cancer eligible for anti-PD-1.

The other ongoing NBTXR3 trials are treating patients with hepatocellular carcinoma (HCC) or liver metastases, locally advanced or unresectable rectal cancer in combination with chemotherapy, head and neck cancer in combination with concurrent chemotherapy, and prostate adenocarcinoma. Furthermore, the company has a large-scale, comprehensive clinical research collaboration with The University of Texas MD Anderson Cancer Center (9 new phase I/II clinical trials in the United States) to evaluate NBTXR3 across head and neck, pancreatic, thoracic, lung, gastrointestinal and genitourinary cancers.

About NANOBIOTIX: http://www.nanobiotix.com

Incorporated in 2003, Nanobiotix is a leading, clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell.

The Nanobiotix philosophy is rooted in designing pioneering, physical-based approaches to bring highly effective and generalized solutions to address unmet medical needs and challenges.

Nanobiotixs first-in-class, proprietary lead technology, NBTXR3, aims to expand radiotherapy benefits for millions of cancer patients. Nanobiotixs Immuno-Oncology program has the potential to bring a new dimension to cancer immunotherapies.

Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP). The Companys headquarters are in Paris, France, with a US affiliate in Cambridge, MA, and European affiliates in France, Spain and Germany

Story continues

1https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/fast-track

Disclaimer

This press release contains certain forward-looking statements concerning Nanobiotix and its business, including its prospects and product candidate development. Such forward-looking statements are based on assumptions that Nanobiotix considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the reference document of Nanobiotix registered with the French Financial Markets Authority (Autorit des Marchs Financiers) under number R.19-018 on April 30, 2019 (a copy of which is available on http://www.nanobiotix.com) and to the development of economic conditions, financial markets and the markets in which Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200210005720/en/

Contacts

Communications Department Brandon Owens VP, Communications +1 (617) 852-4835contact@nanobiotix.com

Pascalyne Wilson Senior Manager, Corporate Marketing +33 (0) 1 70 61 00 18contact@nanobiotix.com

Investor Relations Department Noel Kurdi (US) Director, Investor Relations +1 (646) 241-4400investors@nanobiotix.com

Ricky Bhajun (EU) Senior Manager, Investor Relations +33 (0)1 79 97 29 99investors@nanobiotix.com

Media RelationsFrance TBWA Corporate Pauline Richaud + 33 (0) 437 47 36 42Pauline.richaud@tbwa-corporate.com

US RooneyPartnersMarion Janic +1 (212) 223-4017mjanic@rooneyco.com

Here is the original post:
NANOBIOTIX Announces Fast Track Designation Granted By U.S. FDA For Investigation of First-in-class NBTXR3 In Head and Neck Cancer - Yahoo Finance

Read the Rest...

Out of Touch: Depletion of Mechanosensors Drives Wound-Healing and Cancer – TMC News – Texas Medical Center News

§ February 11th, 2020 § Filed under Nano Medicine Comments Off on Out of Touch: Depletion of Mechanosensors Drives Wound-Healing and Cancer – TMC News – Texas Medical Center News

Additional dates:Next Event:February 11, 2020

Dr. Michael SheetzWelch Professor of BiochemistryMolecular MechanoMedicine ProgramBiochemistry and Molecular BiologyUniversity of Texas Medical BranchGalveston, TX

Out of Touch: Depletion of Mechanosensors Drives Wound-Healing and Cancer

Tuesday, February 11, 202012:30 1:30 PMBRC, 10th Floor, Room 1060 A/B

Abstract: Loss of matrix rigidity sensing in tumor cells enables transformed growth. In over forty tumor lines tested, they lack rigidity sensing complexes because components are altered (about 60% had low Tpm 2.1). The rigidity sensing complex (about 2 m in length) contracts matrix adhesions by ~100nm; and if the force generated is greater than ~25 pN, then cells can grow (Wolfenson et al., 2016. Nat Cell Bio. 18:33). However, if the surface is soft, then the cells apoptose by DAPK1 activation (Qin et al., 2018 BioRxiv. 320739). Although tumor cells grow on soft surfaces, restoration of rigidity sensing restores rigidity-dependent growth (Yang, B. et al., 2020 Nature Mat. 19: 239). Surprisingly, mechanical stretch of transformed cancer cells activates apoptosis through calpain-dependent apoptosis (Tijore et al., 2018 BioRxiv. 491746). Thus, stretch sensitivity is a weakness of cancer cells related to transformation and not to the tissue type or other factors.

Bio: Prof. Michael Sheetz has a long history in mechanobiological research and was most recently the Director of the Mechanobiology Institute at the National University of Singapore. Prior to that he was a Professor at Columbia University where he headed a program in nanomedicine. At Duke University Medical School, he was Chair of Cell Biology from 1990 to 2000. He has received many awards including the Lasker Prize, Wiley and Massry Prizes.

View post:
Out of Touch: Depletion of Mechanosensors Drives Wound-Healing and Cancer - TMC News - Texas Medical Center News

Read the Rest...

The effectiveness of dry salt therapy – The Hindu

§ February 11th, 2020 § Filed under Nano Medicine Comments Off on The effectiveness of dry salt therapy – The Hindu

Is salt therapy truly next-level steam inhalation? The claim is that dry salt therapy, or halotherapy, a drug-free, natural therapy that uses micro-particles of salt, promotes better breathing, healthier skin, improved sleep, physical fitness, endurance, and overall wellness. There are also claims that it helps in respiratory illnesses (asthma, bronchitis) and in skin infections (psoriasis, eczema).

Mitali Sanghi, at Hyderabads recently-opened Salt World, explains that salt therapy uses pharmaceutical-grade dry salt in a comfortable, controlled environment. Within the cave, a device called a halogenerator disperses microscopic salt particles into the room. During the process, tiny particles go deep into the airways and lungs and will also land on the skin.

Natural salt dispersed through micronised inhalers makes the sputum thin and less viscid (sticky), says Dr Mallikarjun Rao S, Hyderabad-based senior consultant pulmonologist. However, he adds that it should be limited to once a week for six-eight weeks, alongside regular medication. I would suggest caution in high blood pressure patients, and for people to consult their pulmonologist/physician before going for a session.

Halotherapy is a blend of western medicine with naturopathy practices used as a cosmetic treatment for the skin. It nourishes the skin and has an effect in treating the symptoms of eczema and rosacea, besides ageing changes. It has a natural anti-inflammatory property, which can help control psoriasis and other skin conditions, plus it can make skin texture younger-looking and brighter, says Dr G Manmohan, Hyderabad-based consultant dermatologist.

But, he adds, it could be the result of a placebo effect. There are many ways of delivering the salt into the body for therapeutic purposes, such as saline solution inhalation, dry salt aerosol inhalation, irrigation, saline lavage and brine baths (creno therapy), he says.

In fact, a literature review of 151 studies published in the International Journal of COPD said, From this review, recommendations for inclusion of halotherapy as a therapy for COPD cannot be made at this point, and there is a need for high quality studies to determine the effectiveness of this therapy.

In Dr Manmohans words, Publicity cannot be taken as proof for treatment purposes.

Verdict: Hype

In this column, we decode health trends and decide if its all just hype or actually happening

You have reached your limit for free articles this month.

Register to The Hindu for free and get unlimited access for 30 days.

Find mobile-friendly version of articles from the day's newspaper in one easy-to-read list.

Enjoy reading as many articles as you wish without any limitations.

A select list of articles that match your interests and tastes.

Move smoothly between articles as our pages load instantly.

A one-stop-shop for seeing the latest updates, and managing your preferences.

We brief you on the latest and most important developments, three times a day.

Not convinced? Know why you should pay for news.

*Our Digital Subscription plans do not currently include the e-paper ,crossword, iPhone, iPad mobile applications and print. Our plans enhance your reading experience.

View post:
The effectiveness of dry salt therapy - The Hindu

Read the Rest...

« Older Entries Newer Entries »



Page 3«..2345..1020..»